BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Loomba R, Ling L, Dinh DM, DePaoli AM, Lieu HD, Harrison SA, Sanyal AJ. The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in NASH. Hepatology 2021;73:126-43. [PMID: 32794259 DOI: 10.1002/hep.31523] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Xiang H, Sun D, Liu X, She Z, Chen Y. The Role of the Intestinal Microbiota in Nonalcoholic Steatohepatitis. Front Endocrinol 2022;13:812610. [DOI: 10.3389/fendo.2022.812610] [Reference Citation Analysis]
2 Yu X, Wang Y, Lai J, Song T, Duan J. Comparative efficacy of exercise training processes in improving nonalcoholic fatty liver disease: a systematic review and meta-analysis. Ir J Med Sci 2022. [PMID: 35366201 DOI: 10.1007/s11845-022-02988-x] [Reference Citation Analysis]
3 Tilg H, Adolph TE, Dudek M, Knolle P. Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. Nat Metab 2021;3:1596-607. [DOI: 10.1038/s42255-021-00501-9] [Reference Citation Analysis]
4 Trauner M, Fuchs CD. Novel therapeutic targets for cholestatic and fatty liver disease. Gut 2022;71:194-209. [PMID: 34615727 DOI: 10.1136/gutjnl-2021-324305] [Reference Citation Analysis]
5 Acharya C, Bajaj JS. Chronic Liver Diseases and the Microbiome-Translating Our Knowledge of Gut Microbiota to Management of Chronic Liver Disease. Gastroenterology 2021;160:556-72. [PMID: 33253686 DOI: 10.1053/j.gastro.2020.10.056] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
6 Bianco C, Casirati E, Malvestiti F, Valenti L. Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets. JHEP Rep 2021;3:100284. [PMID: 34027340 DOI: 10.1016/j.jhepr.2021.100284] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Fuchs CD, Trauner M. Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology. Nat Rev Gastroenterol Hepatol. [DOI: 10.1038/s41575-021-00566-7] [Reference Citation Analysis]
8 Formes H, Bernardes JP, Mann A, Bayer F, Pontarollo G, Kiouptsi K, Schäfer K, Attig S, Nikolova T, Hofmann TG, Schattenberg JM, Todorov H, Gerber S, Rosenstiel P, Bopp T, Sommer F, Reinhardt C. The gut microbiota instructs the hepatic endothelial cell transcriptome. iScience 2021;24:103092. [PMID: 34622147 DOI: 10.1016/j.isci.2021.103092] [Reference Citation Analysis]
9 Ocaña-Wilhelmi L, Martín-Núñez GM, Ruiz-Limón P, Alcaide J, García-Fuentes E, Gutiérrez-Repiso C, Tinahones FJ, Moreno-Indias I. Gut Microbiota Metabolism of Bile Acids Could Contribute to the Bariatric Surgery Improvements in Extreme Obesity. Metabolites 2021;11:733. [PMID: 34822391 DOI: 10.3390/metabo11110733] [Reference Citation Analysis]
10 Sun X, Chi X, Zhao Y, Liu S, Xing H, Sasso FC. Characteristics and Clinical Significance of Intestinal Microbiota in Patients with Chronic Hepatitis B Cirrhosis and Type 2 Diabetes Mellitus. Journal of Diabetes Research 2022;2022:1-14. [DOI: 10.1155/2022/1826181] [Reference Citation Analysis]
11 Radun R, Trauner M. Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities. Semin Liver Dis 2021. [PMID: 34289507 DOI: 10.1055/s-0041-1731707] [Reference Citation Analysis]
12 Albhaisi S, Noureddin M. Current and Potential Therapies Targeting Inflammation in NASH. Front Endocrinol (Lausanne) 2021;12:767314. [PMID: 34925237 DOI: 10.3389/fendo.2021.767314] [Reference Citation Analysis]
13 Filipovic B, Lukic S, Mijac D, Marjanovic-Haljilji M, Vojnovic M, Bogdanovic J, Glisic T, Filipovic N, Al Kiswani J, Djokovic A, Kapor S, Kapor S, Bukumiric Z, Starcevic A. The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2021;22:13219. [PMID: 34948020 DOI: 10.3390/ijms222413219] [Reference Citation Analysis]
14 Song W, Sun LY, Zhu ZJ, Wei L, Qu W, Zeng ZG, Liu Y, Zhang HM, Guo W. Association of Gut Microbiota and Metabolites With Disease Progression in Children With Biliary Atresia. Front Immunol 2021;12:698900. [PMID: 34630385 DOI: 10.3389/fimmu.2021.698900] [Reference Citation Analysis]
15 Zheng Y, Ran Y, Zhang H, Wang B, Zhou L. The Microbiome in Autoimmune Liver Diseases: Metagenomic and Metabolomic Changes. Front Physiol 2021;12:715852. [PMID: 34690796 DOI: 10.3389/fphys.2021.715852] [Reference Citation Analysis]
16 Mayneris-Perxachs J, Cardellini M, Hoyles L, Latorre J, Davato F, Moreno-Navarrete JM, Arnoriaga-Rodríguez M, Serino M, Abbott J, Barton RH, Puig J, Fernández-Real X, Ricart W, Tomlinson C, Woodbridge M, Gentileschi P, Butcher SA, Holmes E, Nicholson JK, Pérez-Brocal V, Moya A, Clain DM, Burcelin R, Dumas ME, Federici M, Fernández-Real JM. Iron status influences non-alcoholic fatty liver disease in obesity through the gut microbiome. Microbiome 2021;9:104. [PMID: 33962692 DOI: 10.1186/s40168-021-01052-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Gryaznova M, Dvoretskaya Y, Burakova I, Syromyatnikov M, Popov E, Kokina A, Mikhaylov E, Popov V. Dynamics of Changes in the Gut Microbiota of Healthy Mice Fed with Lactic Acid Bacteria and Bifidobacteria. Microorganisms 2022;10:1020. [DOI: 10.3390/microorganisms10051020] [Reference Citation Analysis]